Finance

Cell-therapy company updates Q2, reports $1.4 million net loss

Published in Hepatitis Weekly, September 13th, 2004

Chromos Molecular Systems, Inc., (CHR), a company focused on the development and commercialization of immune- and gene-based cell therapies and cell line engineering for biopharmaceutical production, announced financial results and operational highlights for the second quarter ended June 30, 2004.

"The acquisition of CellExSys provides Chromos with a new cell-therapy technology and a strong preclinical pipeline to support product development in the areas of infectious diseases and cancer," said Alistair Duncan, president and CEO of Chromos. "This program accelerates our entry into the clinic, and complements our internal gene-based cell therapy programs, advancing our...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2004-09-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry